File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Optimizing prostate cancer diagnosis: 10-core versus 12-core prostate biopsy protocol

TitleOptimizing prostate cancer diagnosis: 10-core versus 12-core prostate biopsy protocol
Authors
Issue Date2014
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
Hong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 6 How to Cite?
AbstractObjective: To review the prostate cancer detection rate of a new 12-core prostate biopsy protocol. Patients & Methods: From August and October 2011 onwards, 2 additional cores were added to the existing 10-core protocol during transrectal ultrasound-guided prostate biopsy (TRUS-Bx) in the diagnosis of early prostate cancer in Queen Mary and Tung Wah Hospitals respectively. Patient demographics, cancer detection rates and complications using the new 12-core protocol were retrieved from our prospective database and compared with those using the 10-core protocol. Results: From January 2010 to March 2013, 626 and 631 patients underwent TRUS-Bx using a 10-core and 12-core protocol respectively. Overall for clinically benign prostates, there was a trend towards superior cancer detection using the 12-core protocol (5.3% vs. 7.2%, p = 0.077). Subgroup analysis showed the 12-core protocol had significantly higher cancer detection in patients with pre-biopsy PSA <10 ng/ml (OR 1.69; 95% CI 1.10–2.56; p = 0.019) and prostates sized 20–40 ml (OR 1.96; 95% CI 1.16–3.30; p = 0.014). There was a trend towards increased rate of septic complications after 12-core TRUS-Bx (1.9% vs. 3.1%; OR 1.68; 95% CI 0.95–2.97; p = 0.09). Conclusion: 12-core TRUS-Bx can detect more prostate cancer in selected groups of patients, namely those with PSA <10 ng/ml and prostates sized 20–40 ml. Post-biopsy infection rate has increased with the new protocol marginally, owing to the increased number of cores.
DescriptionOral Presentation
Persistent Identifierhttp://hdl.handle.net/10722/193959
ISSN
2015 Impact Factor: 4.387
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorLai, TCTen_US
dc.contributor.authorTsu, HLJen_US
dc.contributor.authorNg, CMen_US
dc.contributor.authorWong, EMHen_US
dc.contributor.authorHo, KLen_US
dc.contributor.authorYiu, MKen_US
dc.date.accessioned2014-01-28T06:38:21Z-
dc.date.available2014-01-28T06:38:21Z-
dc.date.issued2014en_US
dc.identifier.citationHong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 6en_US
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/193959-
dc.descriptionOral Presentation-
dc.description.abstractObjective: To review the prostate cancer detection rate of a new 12-core prostate biopsy protocol. Patients & Methods: From August and October 2011 onwards, 2 additional cores were added to the existing 10-core protocol during transrectal ultrasound-guided prostate biopsy (TRUS-Bx) in the diagnosis of early prostate cancer in Queen Mary and Tung Wah Hospitals respectively. Patient demographics, cancer detection rates and complications using the new 12-core protocol were retrieved from our prospective database and compared with those using the 10-core protocol. Results: From January 2010 to March 2013, 626 and 631 patients underwent TRUS-Bx using a 10-core and 12-core protocol respectively. Overall for clinically benign prostates, there was a trend towards superior cancer detection using the 12-core protocol (5.3% vs. 7.2%, p = 0.077). Subgroup analysis showed the 12-core protocol had significantly higher cancer detection in patients with pre-biopsy PSA <10 ng/ml (OR 1.69; 95% CI 1.10–2.56; p = 0.019) and prostates sized 20–40 ml (OR 1.96; 95% CI 1.16–3.30; p = 0.014). There was a trend towards increased rate of septic complications after 12-core TRUS-Bx (1.9% vs. 3.1%; OR 1.68; 95% CI 0.95–2.97; p = 0.09). Conclusion: 12-core TRUS-Bx can detect more prostate cancer in selected groups of patients, namely those with PSA <10 ng/ml and prostates sized 20–40 ml. Post-biopsy infection rate has increased with the new protocol marginally, owing to the increased number of cores.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU Internationalen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.titleOptimizing prostate cancer diagnosis: 10-core versus 12-core prostate biopsy protocolen_US
dc.typeConference_Paperen_US
dc.identifier.emailTsu, HLJ: jamestsu@hku.hken_US
dc.identifier.emailHo, KL: hkl218@hkucc.hku.hken_US
dc.identifier.emailYiu, MK: pmkyiu@hku.hken_US
dc.identifier.doi10.1111/bju.12606-
dc.identifier.hkuros227499en_US
dc.identifier.volume113-
dc.identifier.issueSuppl. S1-
dc.identifier.spage6-
dc.identifier.epage6-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats